These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20526574)

  • 1. Salmonella-allies in the fight against cancer.
    Leschner S; Weiss S
    J Mol Med (Berl); 2010 Aug; 88(8):763-73. PubMed ID: 20526574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications.
    Dróżdż M; Makuch S; Cieniuch G; Woźniak M; Ziółkowski P
    Life Sci; 2020 Nov; 261():118296. PubMed ID: 32822716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Cancer Therapy Using Engineered Salmonella typhimurium.
    Zheng JH; Min JJ
    Chonnam Med J; 2016 Sep; 52(3):173-84. PubMed ID: 27689027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facultative Anaerobes Shape Multispecies Biofilms Composed of Meat Processing Surface Bacteria and Escherichia coli O157:H7 or Salmonella enterica Serovar Typhimurium.
    Visvalingam J; Wang H; Ells TC; Yang X
    Appl Environ Microbiol; 2019 Sep; 85(17):. PubMed ID: 31253683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific gene delivery using genetically engineered bacteria.
    Theys J; Barbé S; Landuyt W; Nuyts S; Van Mellaert L; Wouters B; Anné J; Lambin P
    Curr Gene Ther; 2003 Jun; 3(3):207-21. PubMed ID: 12762480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New technologies in developing recombinant-attenuated bacteria for cancer therapy.
    Liang K; Liu Q; Kong Q
    Biotechnol Bioeng; 2021 Feb; 118(2):513-530. PubMed ID: 33038015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic intervention alternatives in cancer, using attenuated live bacterial vectors: Salmonella enterica as a carrier of heterologous molecules].
    Hernández-Luna MA; Luria-Pérez R; Huerta-Yépez S
    Rev Invest Clin; 2013; 65(1):65-73. PubMed ID: 23745445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically engineered Salmonella Typhimurium: Recent advances in cancer therapy.
    Liang K; Liu Q; Li P; Luo H; Wang H; Kong Q
    Cancer Lett; 2019 Apr; 448():168-181. PubMed ID: 30753837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting solid tumors with non-pathogenic obligate anaerobic bacteria.
    Taniguchi S; Fujimori M; Sasaki T; Tsutsui H; Shimatani Y; Seki K; Amano J
    Cancer Sci; 2010 Sep; 101(9):1925-32. PubMed ID: 20579076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Containment of tumor-colonizing bacteria by host neutrophils.
    Westphal K; Leschner S; Jablonska J; Loessner H; Weiss S
    Cancer Res; 2008 Apr; 68(8):2952-60. PubMed ID: 18413765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain.
    Yu B; Yang M; Shi L; Yao Y; Jiang Q; Li X; Tang LH; Zheng BJ; Yuen KY; Smith DK; Song E; Huang JD
    Sci Rep; 2012; 2():436. PubMed ID: 22666539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nontyphoidal Salmonella: a potential anticancer agent.
    Jazeela K; Chakraborty A; Karunasagar I; Deekshit VK
    J Appl Microbiol; 2020 Jan; 128(1):2-14. PubMed ID: 31038778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha.
    Leschner S; Westphal K; Dietrich N; Viegas N; Jablonska J; Lyszkiewicz M; Lienenklaus S; Falk W; Gekara N; Loessner H; Weiss S
    PLoS One; 2009 Aug; 4(8):e6692. PubMed ID: 19693266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in tumor-therapy using genetically modified Salmonella].
    Liang K; Zhao X; Yi J; Liu Q; Liu Q; Kong Q
    Sheng Wu Gong Cheng Xue Bao; 2016 May; 32(5):565-576. PubMed ID: 29019195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteria and genetically modified bacteria as cancer therapeutics: Current advances and challenges.
    Nallar SC; Xu DQ; Kalvakolanu DV
    Cytokine; 2017 Jan; 89():160-172. PubMed ID: 26778055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live bacteria as anticancer agents and tumor-selective protein delivery vectors.
    Bermudes D; Zheng LM; King IC
    Curr Opin Drug Discov Devel; 2002 Mar; 5(2):194-9. PubMed ID: 11926125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preclinical discovery of bacterial therapy for the treatment of metastatic cancer with unique advantages.
    Hoffman RM
    Expert Opin Drug Discov; 2012 Jan; 7(1):73-83. PubMed ID: 22468895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting tumors with salmonella Typhimurium- potential for therapy.
    Wall DM; Srikanth CV; McCormick BA
    Oncotarget; 2010 Dec; 1(8):721-728. PubMed ID: 21321381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic Biology Medicine and Bacteria-Based Cancer Therapeutics.
    Lee J; Keates AC; Li CJ
    Methods Mol Biol; 2021; 2323():267-280. PubMed ID: 34086287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-targeting amino acid auxotrophic Salmonella typhimurium.
    Hoffman RM
    Amino Acids; 2009 Sep; 37(3):509-21. PubMed ID: 19291366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.